Patheon Expands Comprehensive API Services with Acquisition of IRIX Pharmaceuticals

Patheon has reached a definitive agreement to acquire IRIX Pharmaceuticals, a company headquartered in Florence, SC. that specializes in difficult-to-manufacture API needs for drugs from early and late development, through commercial launch. Patheon will purchase IRIX and expects to close the transaction in the next 60 days.

Patheon secures additional API development and manufacturing services in the US, including high-potency (SafeBridge Class IV certified) and controlled substances (Schedule 1–4), better meeting customers’ most challenging needs. IRIX has a well-established reputation for the optimization of chemical processes and scale up for commercial API manufacturing at sites in Greenville and Florence, SC.

“This is an exciting time at Patheon as we continue to secure important capabilities around the globe to address growing customer needs,” said Lukas Utiger, president, DPx Fine Chemicals and leader of the Patheon OneSourceTMoffering. “With this deal we expand our Patheon OneSource integrated offering and leverage years of operational experience and scientific excellence at IRIX to complement Patheon’s existing API operations in Europe.”

Patheon and IRIX combined, offer an array of cutting edge process technologies, including biocatalysis, homogeneous catalysis and microreactors, and are well positioned to address an extensive range of supply chain issues for customers.

“Combining companies with shared commitments to both scientific excellence and customer service drives industry excellence, and we are excited to become part of the Patheon network,” said Guy Steenrod, CEO, IRIX. “This is a strategic deal that allows us to help customers solve complex challenges with comprehensive, integrated solutions.”